Kamada Ltd. (NASDAQ:KMDA)’s share price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.00 and traded as low as $5.72. Kamada shares last traded at $5.73, with a volume of 8,740 shares.
A number of research analysts recently commented on KMDA shares. Zacks Investment Research cut Kamada from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 24th. Chardan Capital reiterated a “buy” rating and issued a $7.00 price objective on shares of Kamada in a report on Friday, May 17th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $8.17.
The firm has a market cap of $231.09 million, a PE ratio of 10.31 and a beta of 1.18. The business’s fifty day moving average is $5.67. The company has a debt-to-equity ratio of 0.04, a current ratio of 5.29 and a quick ratio of 3.82.
Several institutional investors have recently bought and sold shares of the company. Marshall Wace LLP acquired a new stake in shares of Kamada during the first quarter worth about $276,000. Meitav Dash Investments Ltd. boosted its stake in shares of Kamada by 3.1% during the first quarter. Meitav Dash Investments Ltd. now owns 909,912 shares of the biotechnology company’s stock worth $5,201,000 after buying an additional 27,405 shares during the period. Acadian Asset Management LLC boosted its stake in shares of Kamada by 41.8% during the first quarter. Acadian Asset Management LLC now owns 945,878 shares of the biotechnology company’s stock worth $5,422,000 after buying an additional 278,674 shares during the period. Nkcfo LLC acquired a new stake in shares of Kamada during the first quarter worth about $26,000. Finally, Norges Bank acquired a new stake in shares of Kamada during the fourth quarter worth about $219,000. 12.98% of the stock is currently owned by institutional investors and hedge funds.
About Kamada (NASDAQ:KMDA)
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency.
Featured Story: Cost of Equity For A Business, Investors
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.